Boston Scientific Sets Q2 Adjusted EPS Outlook at 82c-84c
Summary
Boston Scientific has issued its adjusted EPS guidance for the second quarter, projecting a range of $0.82 to $0.84. This new forward-looking guidance follows the company's strong 2025 financial results and strategic acquisitions detailed in its recent 10-K filing. This guidance is a material update for investors, as it sets the financial expectations for the upcoming quarter and will be a key input for analyst models and investor sentiment. Traders will closely compare this range against current consensus estimates to assess potential upside or downside. The market's reaction will depend on how this guidance aligns with or deviates from those expectations, and investors will monitor future earnings calls for performance updates.
At the time of this announcement, BSX was trading at $60.10 on NYSE in the Life Sciences sector, with a market capitalization of approximately $88.5B. The 52-week trading range was $59.39 to $109.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.